

Verein für
Association pour le
Associazione per il



medizinische Qualitätskontrolle
contrôle de qualité médical
controllo di qualità medico

Survey Report

2020 - 2

Survey Specimens

The homogeneity and stability of all specimens were checked before and/or during shipment and no irregularities were noted. The suitability tests were performed by the laboratories of the Universitätsspital Zürich (University Hospital Zurich) (<http://www.uzl.usz.ch/>).

The following survey specimens were produced specifically for MQ by a sub-contractor:
B1 Strep A Test, B2 Uricult, H4 Parasitic Hematology, K14 tumor marker

Determination of target values

For each target value, the type of determination per ISO17043: 2010 B2.1 is indicated (column "type"):

- a Value known due to production.
- b Certified reference value for use with special specimens
- c Reference value determined by analysis
- d Consensus values of expert laboratories
- e Consensus values of the participants

For methods groups with more than 9 participants, consensus values of the participants ("e") are generally determined. In order to calculate the target values, we use the mean value of the method group. Values that differ more than 1.5 times the QUALAB-tolerance are outliers and are not used to calculate the target value. Starting point for the elimination of outliers are the values of our suitability tests. In order to provide all participants with target values that are as meaningful as possible, other methods may also be applied for smaller method groups.

Uncertainty of the determined target values

The standard uncertainty (u_x) is calculated using the following formula (ISO13528):

$$u_x = (\text{target value}/100) * (1.25/\text{square root of "number of participants"}) * \%CV$$

- u_x has the same unit as the target value
- u_x can be compared with the standard deviation of the participants' collective ($SD = \text{target value} * \%CV/100$)
- For participant numbers > 18 , the standard uncertainty (u_x) is significantly lower than the scatter of the collective participants and can be neglected.


QUALAB and MQ tolerances

For all mandatory analyzes, QUALAB tolerances are used (www.qualab.ch, external quality control). For non-mandatory analyzes, the tolerances are specified by MQ's survey specimen leader.

If the determined uncertainty, u_x , of the target value is greater than 15% of the QUALAB or MQ tolerance, the letter indicating the type of target detection is marked with an additional star (example "e*"). Thereby, we are alerting the participants to the fact that the uncertainty of the target value can have an impact on the evaluation.

Graphics

The results are shown graphically as follows:



Comparison of Devices

The data in this report allows you to compare the performance of different devices. However, remember to consider the following:

- The chemical control K1 is a ready-to-use commercial control serum. Even if the specimen is of human origin, it is possible that matrix effects occur. These are device-specific and result in different target values.
- Only one specimen was measured. Since the scatter of the results is dependent on the nature of the specimen (matrix effects) and on the signal strength, the determined coefficient of variations (CV in %) cannot be applied generally.
- A large number of runaways is due to administrative errors (wrong unit, results mixed up) or to operator errors (wrong sample, not correctly taken up in solution, not mixed well) and has nothing to do with the type of device.


Zürich, 28.6.2020

Dr. R. Fried
Survey Director

Publication of this report or any portion thereof without our prior written consent is not permitted. The original is archived at www.mqzh.ch

G01 Coagulation INR

INR




QUALAB Toleranz : 15 %


INR ()

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Neoplastin Plus	7	85.7	0.0	14.3	2.19	3.7	e
2 Innovin	13	100.0	0.0	0.0	1.73	5.1	e
3 Recombiplastin 2G	10	100.0	0.0	0.0	1.74	4.7	e
4 Eurolyser	4	75.0	0.0	25.0	1.39	3.0	e
5 Other methods	9	100.0	0.0	0.0	1.73	4.5	e
6 Neoplastin R	11	100.0	0.0	0.0	1.77	4.0	e


Fibrinogen OA



Activated Prothrombin Time




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Other methods	7	100.0	0.0	0.0	46.8	12.5	e*
2 Actin FS	8	100.0	0.0	0.0	42.0	12.4	e*
3 Pathromtin SL	4	100.0	0.0	0.0	71.0	5.2	e
4 Stago/STA	13	100.0	0.0	0.0	51.6	5.0	e
5 aPTT-SP	5	100.0	0.0	0.0	40.8	5.0	e


INR CoaguChek

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 CoaguChek Pro II	536	98.9	0.2	0.9	2.9	3.8	e

Prothrombin time NT




Faktor II





Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	5	100.0	0.0	0.0	92.0	5.0	e

Fibrinogen N




Faktor V




aPTT N

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Actin FS	4	100.0	0.0	0.0	25.3	5.9	e
2 Other methods	10	100.0	0.0	0.0	32.2	11.5	e*
3 Stago/STA	16	100.0	0.0	0.0	32.6	5.3	e
4 aPTT-SP	9	100.0	0.0	0.0	27.6	5.4	e

Faktor VII




Prothrombin time HT




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Neoplastin R	9	100.0	0.0	0.0	94	4.2	e
2 Innovin	6	100.0	0.0	0.0	94	3.4	e
3 all Participants	10	100.0	0.0	0.0	98	5.6	e
4 Recombiplastin 2G	4	100.0	0.0	0.0	108	5.9	e*

Anti-FXa (unfrakt-Heparin)




Fibrinogen H




QUALAB Toleranz : 15 %

Fibrinogen H (g/l)


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Siemens Thrombin	5	100.0	0.0	0.0	2.99	5.3	e*
2 Stago/STA	12	100.0	0.0	0.0	3.18	3.2	e
3 Fibrinogen Q.F.A.	9	77.8	11.1	11.1	2.86	8.6	e*

aPTT H


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Actin FS	5	80.0	20.0	0.0	44.0	12.5	e*
2 Stago/STA	8	100.0	0.0	0.0	52.2	3.1	e
3 aPTT-SP	9	100.0	0.0	0.0	64.1	7.6	e

D-dimer


CoaguChek APTT




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 CoaguChek Pro II	7	100.0	0.0	0.0	45.6	6.4	e

INR CCXS


Nr.	Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1	CoaguChek XS	1791	98.9	0.5	0.6	1.9	3.4	e

INR HC

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Hemochron j.	9	100.0	0.0	0.0	5.0	4.9	e

INR MI


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 MicroINR	129	75.2	17.8	7.0	2.0	8.2	e

INR Xprecia


QUALAB Toleranz : 15 %
(< 1.3: +/- 0.2)

INR Xprecia ()


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Xprecia	62	100.0	0.0	0.0	1.1	4.5	e

INR Lumira Dx


Anti-FXa (LMW-Heparin)



Anti-FXa (Rivaroxaban)




Anti-FXa (Apixaban)




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	6	100.0	0.0	0.0	82.75	10.4	e*


Hemoglobin



Hemoglobin



Hematocrit




QUALAB Toleranz : 9 %

Hematocrit (l/l)

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Automat	18	83.3	5.6	11.1	0.37	5.9	e*
2 Centrifuge	5	100.0	0.0	0.0	0.39	2.6	e*
3 Sysmex X	42	97.6	0.0	2.4	0.39	3.1	e
4 Advia 120	6	100.0	0.0	0.0	0.36	1.2	e
5 Yumizer/Pentra	4	100.0	0.0	0.0	0.35	3.3	e*
6 Sysmex	6	100.0	0.0	0.0	0.39	2.8	e*

Hematocrit




QUALAB Toleranz : 9 %

Hematocrit (l/l)


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Sysmex KX21	245	98.0	0.8	1.2	0.35	2.2	e
2 Sysmex PocH - 100i	195	97.5	1.5	1.0	0.38	2.9	e
3 Sysmex XP 300	542	97.7	0.6	1.7	0.36	2.2	e
4 Mythic	295	95.6	2.4	2.0	0.38	3.9	e
5 Swelab	44	100.0	0.0	0.0	0.38	3.3	e
6 Abacus Junior	4	100.0	0.0	0.0	0.39	2.3	e*
7 Medonic	7	71.4	28.6	0.0	0.38	6.1	e*
8 Celltac Alpha (Nihon)	82	98.8	0.0	1.2	0.38	2.3	e
9 Samsung HC10	36	94.4	5.6	0.0	0.40	3.9	e
10 Micros 60	166	88.6	7.8	3.6	0.35	4.7	e

Erythrocytes




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Automat	16	100.0	0.0	0.0	4.21	6.9	e
2 Sysmex X	42	97.6	0.0	2.4	4.23	1.7	e
3 Advia 120	6	100.0	0.0	0.0	4.26	1.2	e
4 Yumizen/Pentra	4	100.0	0.0	0.0	4.21	2.0	e
5 Sysmex	6	100.0	0.0	0.0	4.21	1.7	e

Erythrocytes




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Sysmex KX21	245	98.8	0.4	0.8	4.16	2.5	e
2 Sysmex PocH - 100i	196	99.0	1.0	0.0	4.32	4.6	e
3 Sysmex XP 300	542	98.7	0.6	0.7	4.16	2.8	e
4 Mythic	295	98.3	0.3	1.4	4.19	4.2	e
5 Swelab	44	97.7	0.0	2.3	4.24	1.7	e
6 Abacus Junior	5	100.0	0.0	0.0	4.32	4.9	e
7 Medonic	7	100.0	0.0	0.0	4.25	5.2	e
8 Celltac Alpha (Nihon)	82	98.8	1.2	0.0	4.27	4.1	e
9 Samsung HC10	36	100.0	0.0	0.0	4.23	2.8	e
10 Micros 60	166	96.4	3.0	0.6	4.05	7.2	e

Leucocytes




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Automat	14	100.0	0.0	0.0	7.42	6.7	e
2 Microscopic	20	90.0	10.0	0.0	6.44	13.7	e*
3 Sysmex X	42	100.0	0.0	0.0	7.49	5.2	e
4 Advia 120 (Perox)	6	100.0	0.0	0.0	6.55	10.2	e*
5 Yumizer/Pentra	4	0.0	50.0	50.0	5.62	47.3	e*
6 Sysmex	6	100.0	0.0	0.0	7.48	3.4	e

Leucocytes



Thrombocytes




QUALAB Toleranz : 25 %


Thrombocytes (G/l)

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Automat	14	100.0	0.0	0.0	271.4	11.7	e*
2 Microscopic	13	84.6	15.4	0.0	250.8	16.4	e*
3 Sysmex X	42	100.0	0.0	0.0	280.3	4.4	e
4 Advia 120	6	100.0	0.0	0.0	265.5	3.9	e
5 Yumizer/Pentra	4	100.0	0.0	0.0	297.5	14.1	e*
6 Sysmex	6	100.0	0.0	0.0	280.5	4.3	e

Thrombocytes




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Sysmex KX21	245	99.6	0.0	0.4	281.2	4.7	e
2 Sysmex PocH - 100i	195	100.0	0.0	0.0	292.6	4.9	e
3 Sysmex XP 300	542	99.0	0.4	0.6	291.2	4.9	e
4 Mythic	295	95.2	3.4	1.4	257.9	10.9	e
5 Swelab	44	97.7	2.3	0.0	264.3	8.2	e
6 Abacus Junior	5	100.0	0.0	0.0	296.0	5.8	e
7 Medonic	7	100.0	0.0	0.0	270.0	7.0	e
8 Celltac Alpha (Nihon)	82	98.8	0.0	1.2	265.8	6.9	e
9 Samsung HC10	36	97.2	0.0	2.8	292.8	8.2	e
10 Micros 60	166	99.4	0.0	0.6	267.0	8.6	e

Hemoglobin H2


QUALAB Toleranz : 9 %

Hemoglobin H2 (g/l)


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Zybio Z3	17	100.0	0.0	0.0	118.4	4.4	e
2 Abx Micros	154	96.8	0.6	2.6	113.8	3.3	e
3 Microsemi	758	98.7	0.4	0.9	117.2	2.0	e

Hematocrit H2


Leucocytes H2



Thrombocytes H2




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Zybio Z3	17	100.0	0.0	0.0	297.2	5.2	e
2 Abx Micros	154	99.4	0.6	0.0	264.2	7.7	e
3 Microsemi	759	98.2	0.9	0.9	269.7	6.3	e

Erythrocytes H2


QUALAB Toleranz : 25 %

Erythrocytes H2 (T/I)

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Zybio Z3	17	100.0	0.0	0.0	3.96	3.3	e
2 Abx Micros	154	98.7	1.3	0.0	3.90	5.3	e
3 Microsemi	759	98.1	0.8	1.1	3.85	3.7	e


CRP H2

Hemoglobin BG




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 iStat	5	100.0	0.0	0.0	187.0	3.7	e*

Hematocrit



Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 iStat	7	100.0	0.0	0.0	0.55	3.5	e*
2 EPOC	7	100.0	0.0	0.0	0.51	5.7	e*

Hemoglobin




QUALAB Toleranz : 9 %


Hemoglobin (g/l)

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Sysmex	66	100.0	0.0	0.0	159.6	1.0	e
2 Advia	6	100.0	0.0	0.0	161.5	1.7	e
3 Yumizen/Pentra	13	100.0	0.0	0.0	162.7	1.5	e

Hematocrit



Erythrocytes




QUALAB Toleranz : 25 %


Erythrocytes (T/l)

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Sysmex	66	100.0	0.0	0.0	5.58	1.1	e
2 Advia	6	100.0	0.0	0.0	5.57	1.5	e
3 Yumizen/Pentra	13	92.3	0.0	7.7	5.47	2.2	e


Leucocytes



Thrombocytes



Neutrophils




MQ tolerance : 25 %

Neutrophils (G/l)


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Sysmex	66	100.0	0.0	0.0	3.12	3.3	e
2 Advia	6	100.0	0.0	0.0	3.17	6.0	e
3 Yumizen/Pentra	13	92.3	0.0	7.7	2.91	7.4	e

Lymphocytes




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Sysmex	66	100.0	0.0	0.0	2.23	3.7	e
2 Advia	6	100.0	0.0	0.0	2.10	6.5	e
3 Yumizen/Pentra	13	100.0	0.0	0.0	2.27	10.3	e

Monocytes




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Sysmex	66	98.5	1.5	0.0	0.52	11.5	e
2 Advia	6	100.0	0.0	0.0	0.35	17.6	e*
3 Yumizen/Pentra	13	76.9	23.1	0.0	0.45	28.9	e*

Eosinophils




Basophiles



MQ tolerance : 80 %
(< 0.10: +/- 0.08 G/l)

Basophiles (G/l)


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Sysmex	65	100.0	0.0	0.0	0.05	38.2	e
2 Advia	6	100.0	0.0	0.0	0.05	58.8	e*
3 Yumizen/Pentra	13	100.0	0.0	0.0	0.05	44.7	e*


MCV

MQ tolerance : 25 %

MCV (fl)

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Sysmex	59	100.0	0.0	0.0	88.2	4.0	e
2 Advia	6	100.0	0.0	0.0	86.4	4.6	e
3 Yumizen/Pentra	11	100.0	0.0	0.0	85.9	1.5	e


MCH

MCHC

MQ tolerance : 25 %

MCHC (g/l)

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Sysmex	59	100.0	0.0	0.0	326	4.2	e
2 Advia	6	100.0	0.0	0.0	335	5.5	e
3 Yumizen/Pentra	11	100.0	0.0	0.0	345	2.6	e


RDW

MQ tolerance : 25 %

RDW (%)

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Sysmex	58	98.3	0.0	1.7	14.6	4.6	e
2 Advia	5	100.0	0.0	0.0	14.8	6.0	e
3 Yumizen/Pentra	11	100.0	0.0	0.0	13.8	9.5	e

Immature Granulocytes




MQ tolerance : 25 %
(< 0.10: +/- 0.10 G/l)

Immature Granulocytes (G/l)


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Sysmex	51	100.0	0.0	0.0	0.02	65.9	e*

Reticulocytes




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Sysmex	34	97.1	2.9	0.0	69.9	13.1	e
2 Advia	4	100.0	0.0	0.0	69.1	16.5	a


Hämolyseindex Probe A




Hämolyseindex Probe B




Erythrocyte sedimentation rate 1h




Erythrocyte sedimentation rate 2h

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 BD Seditainer	5	100.0	0.0	0.0	150	6.9	e

CRP





Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas b101	234	99.1	0.0	0.9	27.1	4.5	e
2 Cobas	20	100.0	0.0	0.0	28.8	7.3	e
3 Turbidimetry	14	100.0	0.0	0.0	29.6	7.7	e
4 Afinion	1299	98.9	0.3	0.8	28.4	6.6	e
5 NycoCard SingleTest-	135	79.3	9.6	11.1	27.1	13.0	e
6 Quick Read go	109	97.3	0.9	1.8	28.6	6.9	e
7 Eurolyser	99	81.8	7.1	11.1	38.7	11.0	e
8 Fuji Dri-Chem	14	71.4	14.3	14.3	32.7	15.4	e*
9 Autolyser/DiaSys	11	81.8	0.0	18.2	28.6	5.4	e
10 Piccolo	5	100.0	0.0	0.0	33.3	5.5	e
11 Celltac chemi	44	93.2	6.8	0.0	29.8	8.2	e


CRP

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 QuikRead (Vollblut)	45	93.4	2.2	4.4	47.7	5.7	e


CRP




IgG

IgA


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Turbidimetry	15	100.0	0.0	0.0	2.3	3.9	e
2 Nephelometry	5	100.0	0.0	0.0	2.5	6.6	e

IgM

IgE


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	5	80.0	20.0	0.0	108	16.1	e*
2 Cobas	5	100.0	0.0	0.0	119	10.1	e*

Alpha-1-Antitrypsin




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	8	100.0	0.0	0.0	1.21	4.2	e

Anti-Streptolysin-Antibodies




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	11	100.0	0.0	0.0	170	4.3	e

Complement C3




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	14	100.0	0.0	0.0	1.63	5.6	e

Complement C4




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	13	100.0	0.0	0.0	0.29	7.5	e

Haptoglobin




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	17	100.0	0.0	0.0	1.46	2.6	e

Transferrin




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	25	100.0	0.0	0.0	2.49	2.9	e

Beta-2 microglobuline




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	4	100.0	0.0	0.0	2.26	4.9	e

Rheumatoid factor



Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	5	100.0	0.0	0.0	32.0	8.9	e*

Ceruloplasmin




MQ tolerance : 25 %

Ceruloplasmin (mg/l)


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Siemens	4	100.0	0.0	0.0	360.00	10.9	e*
2 all Participants	4	100.0	0.0	0.0	267.50	6.1	e*

Prealbumin




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	15	100.0	0.0	0.0	229.9	4.2	e

Soluble transferrin receptor




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	7	100.0	0.0	0.0	3.5	3.1	e

CRP HS


QUALAB Toleranz : 21 %
(< 10.00: +/- 2.00 mg/l)

CRP HS (mg/l)


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Turbidimetry	5	100.0	0.0	0.0	5.52	3.9	e

Lipoprotein (a)


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Others	4	100.0	0.0	0.0	64	7.8	e*

CRP

Albumine




Alkaline phosphatase




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 IFCC	7	100.0	0.0	0.0	214	2.4	e
2 Cobas	22	100.0	0.0	0.0	177	5.3	e
3 Reflotron	466	95.3	2.6	2.1	350	7.0	e
4 Fuji Dri-Chem	803	99.3	0.1	0.6	189	5.7	e
5 Spotchem/Ready	54	90.7	7.4	1.9	241	9.3	e
6 Spotchem D-Concept	299	98.0	0.7	1.3	203	6.7	e
7 Hitachi S40/M40	13	100.0	0.0	0.0	149	3.6	e
8 Beckman	12	100.0	0.0	0.0	243	7.1	e
9 Dimension	4	100.0	0.0	0.0	193	2.8	e
10 Piccolo	42	100.0	0.0	0.0	246	3.4	e
11 Abx Mira	8	87.5	12.5	0.0	217	11.3	e*
12 Autolyser/DiaSys	18	100.0	0.0	0.0	190	6.9	e

Amylase




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 IFCC	7	100.0	0.0	0.0	283	6.1	e*
2 Cobas	8	100.0	0.0	0.0	260	2.8	e
3 Reflotron	125	96.0	3.2	0.8	230	7.0	e
4 Fuji Dri-Chem	589	99.8	0.2	0.0	200	4.2	e
5 Spotchem/Ready	39	89.7	0.0	10.3	86	9.4	e
6 Spotchem D-Concept	237	99.6	0.0	0.4	148	5.7	e
7 Architect	5	100.0	0.0	0.0	336	2.8	e
8 Piccolo	42	100.0	0.0	0.0	243	4.0	e
9 Abx Mira	4	100.0	0.0	0.0	326	1.3	e
10 Hitachi S40/M40	6	100.0	0.0	0.0	303	5.1	e
11 Autolyser/DiaSys	7	100.0	0.0	0.0	242	2.8	e

Pancreatic amylase




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 IFCC	15	100.0	0.0	0.0	228	4.6	e
2 Cobas	12	100.0	0.0	0.0	238	2.3	e
3 Reflotron	318	96.8	1.6	1.6	209	6.3	e
4 Autolyser/DiaSys	9	100.0	0.0	0.0	226	4.9	e

Bilirubin




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Standard chemistry	11	100.0	0.0	0.0	48.8	12.6	e*
2 Cobas	19	100.0	0.0	0.0	46.5	4.8	e
3 Reflotron	350	96.3	2.0	1.7	53.6	7.5	e
4 Fuji Dri-Chem	637	97.3	1.4	1.3	49.8	6.3	e
5 Spotchem/Ready	49	87.8	10.2	2.0	55.6	11.2	e
6 Spotchem D-Concept	239	97.9	0.8	1.3	45.0	7.5	e
7 Beckman	10	100.0	0.0	0.0	58.5	7.1	e*
8 Piccolo	48	95.8	2.1	2.1	41.4	7.0	e
9 Abx Mira	9	100.0	0.0	0.0	44.7	10.6	e*
10 Hitachi S40/M40	11	100.0	0.0	0.0	52.3	5.7	e
11 Autolyser/DiaSys	16	100.0	0.0	0.0	48.5	3.2	e

Bilirubin direct




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Autolyser/DiaSys	4	100.0	0.0	0.0	31.2	10.8	e*
2 Fuji Dri-Chem	25	92.0	0.0	8.0	27.8	5.6	e

Calcium




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Standard chemistry	25	96.0	4.0	0.0	2.37	3.3	e
2 Cobas	22	100.0	0.0	0.0	2.42	2.6	e
3 Fuji Dri-Chem	355	96.4	2.8	0.8	2.47	4.1	e
4 Spotchem/Ready	16	93.7	6.3	0.0	1.97	5.3	e*
5 Spotchem D-Concept	95	91.6	2.1	6.3	1.99	3.7	e
6 Piccolo	46	100.0	0.0	0.0	2.41	2.3	e
7 Hitachi S40/M40	9	100.0	0.0	0.0	2.35	4.6	e*
8 Autolyser/DiaSys	9	100.0	0.0	0.0	2.33	2.5	e

Calcium ISE




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 iStat Chem8	5	100.0	0.0	0.0	0.93	1.1	e


Chloride



Cholesterol total




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Imuchem / Simplex	7	85.7	0.0	14.3	4.40	5.0	e*
2 Standard chemistry	24	91.7	0.0	8.3	4.00	3.1	e
3 Cobas	20	100.0	0.0	0.0	3.80	2.3	e
4 Reflotron	407	97.8	1.5	0.7	3.57	3.4	e
5 Fuji Dri-Chem	791	96.2	2.7	1.1	3.78	4.5	e
6 Spotchem/Ready	74	93.2	2.7	4.1	3.90	4.3	e
7 Spotchem D-Concept	300	95.7	3.3	1.0	3.79	4.5	e
8 Piccolo	23	100.0	0.0	0.0	3.94	2.0	e
9 Cholestech LDX	317	97.4	1.3	1.3	3.96	3.9	e
10 Abx Mira	7	100.0	0.0	0.0	4.07	2.2	e
11 Hitachi S40/M40	11	100.0	0.0	0.0	3.92	1.9	e
12 Autolyser/DiaSys	18	88.8	5.6	5.6	3.89	5.4	e*
13 Other methods	5	80.0	0.0	20.0	3.09	1.1	e


Cholesterin HDL

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Imuchem / Simplex	7	71.4	28.6	0.0	1.00	21.1	e*
2 Wet chemistry, direc	12	100.0	0.0	0.0	1.21	7.7	e
3 Cobas	18	100.0	0.0	0.0	1.00	5.2	e
4 Reflotron	287	77.7	13.2	9.1	0.88	13.4	e
5 Fuji Dri-Chem	768	98.8	0.3	0.9	1.40	3.5	e
6 Spotchem/Ready	67	94.0	6.0	0.0	0.60	11.1	e
7 Spotchem D-Concept	292	90.1	8.9	1.0	0.66	12.1	e
8 Dimension	4	100.0	0.0	0.0	1.52	5.2	e*
9 Piccolo	21	100.0	0.0	0.0	0.97	10.9	e
10 Pentra>Selectra	11	90.9	9.1	0.0	0.81	11.5	e*
11 Cholestech LDX	317	88.4	6.6	5.0	1.08	10.6	e
12 Hitachi S40/M40	10	100.0	0.0	0.0	1.24	7.0	e
13 Architect	5	100.0	0.0	0.0	1.02	3.0	e
14 Autolyser/DiaSys	18	94.4	5.6	0.0	1.22	6.4	e

Creatine kinase



Cholesterol LDL




QUALAB Toleranz : 18 %

Cholesterol LDL (mmol/l)


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Standard chemistry	8	87.5	0.0	12.5	2.0	8.0	e*
2 Roche, Cobas	8	100.0	0.0	0.0	2.7	5.4	e
3 Hitachi S40/M40	5	100.0	0.0	0.0	1.5	4.4	e
4 Autolyser/DiaSys	13	100.0	0.0	0.0	2.1	8.5	e*
5 Beckman	7	100.0	0.0	0.0	2.5	5.7	e

Iron




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Standard chemistry	15	100.0	0.0	0.0	28	3.4	e
2 Cobas	10	100.0	0.0	0.0	28	1.9	e

Gamma-glutamyltransferase




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Imuchem / Simplex	8	100.0	0.0	0.0	102	9.2	e*
2 Cobas	21	100.0	0.0	0.0	79	7.5	e
3 Reflotron	618	97.1	1.6	1.3	102	6.1	e
4 Fuji Dri-Chem	881	99.3	0.1	0.6	111	5.6	e
5 Spotchem/Ready	81	96.3	3.7	0.0	109	7.3	e
6 Spotchem D-Concept	339	97.9	1.5	0.6	107	7.1	e
7 Selectra/Bolis	6	100.0	0.0	0.0	84	3.6	e
8 Architect	7	100.0	0.0	0.0	77	3.7	e
9 Dimension	8	100.0	0.0	0.0	84	3.1	e
10 IFCC Beckmann	6	100.0	0.0	0.0	82	1.9	e
11 Piccolo	40	100.0	0.0	0.0	74	4.7	e
12 Hitachi S40/M40	14	100.0	0.0	0.0	91	5.9	e
13 Autolyser/DiaSys	18	100.0	0.0	0.0	83	4.4	e

Glucose




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Imuchem / Simplex	7	14.3	14.3	71.4	11.2	11.6	a
2 Standard chemistry	26	92.4	3.8	3.8	11.2	3.2	e
3 Cobas	20	100.0	0.0	0.0	11.4	1.7	e
4 Reflotron	607	91.5	4.9	3.6	10.4	4.7	e
5 Fuji Dri-Chem	836	99.3	0.1	0.6	10.4	2.5	e
6 Spotchem/Ready	74	87.8	8.1	4.1	11.7	5.3	e
7 Spotchem D-Concept	314	84.1	12.1	3.8	11.0	5.7	e
8 Dimension	4	100.0	0.0	0.0	11.2	5.0	e*
9 Piccolo	52	100.0	0.0	0.0	11.1	1.3	e
10 Cholestech LDX	308	92.6	4.5	2.9	10.8	4.7	e
11 Abx Mira	7	100.0	0.0	0.0	11.3	1.9	e
12 Hitachi S40/M40	16	93.7	6.3	0.0	11.2	3.9	e
13 Autolyser/DiaSys	18	100.0	0.0	0.0	10.9	3.4	e
14 iStat Chem8	6	100.0	0.0	0.0	10.2	2.0	e

Glucose




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Accu-Chek Aviva	276	95.7	1.8	2.5	12.8	3.5	e
2 Accu-Chek Inform 2	658	98.7	0.5	0.8	13.0	2.6	e
3 Accu-Check Guide	219	96.3	2.3	1.4	10.8	3.7	e
4 Contour XT	1247	96.6	2.6	0.8	11.1	4.0	e
5 Glucocard	12	91.7	8.3	0.0	16.2	4.2	e*
6 Hemocue 201+ P-equiv	97	93.8	1.0	5.2	12.8	2.6	e
7 Hemocue 201RT P-equi	109	96.3	2.8	0.9	12.8	3.1	e
8 Freestyle Freedom li	5	100.0	0.0	0.0	12.4	2.8	e*
9 Sanofi BG Star	4	75.0	0.0	25.0	15.0	8.8	e*
10 Contour NEXT ONE	8	87.5	12.5	0.0	10.9	4.7	e*


Glucose B




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Hemocue 201+ (alt)	43	90.6	4.7	4.7	12.6	4.4	e
2 AccuChek Sensor	30	100.0	0.0	0.0	11.4	2.8	e
3 OneTouch Verio	25	100.0	0.0	0.0	10.8	2.3	e
4 Contour 2 (5s)	21	100.0	0.0	0.0	8.8	4.6	e
5 Contour (15s)	5	80.0	0.0	20.0	14.8	3.9	e*
6 Healthpro	39	76.9	12.8	10.3	19.9	6.1	e
7 Mylife UNIO	257	94.6	2.7	2.7	13.9	3.7	e
8 mylife Pura	71	80.3	2.8	16.9	13.2	4.2	e
9 Omnitest	19	94.7	5.3	0.0	15.7	4.9	e*
10 Alpha Check	23	87.0	0.0	13.0	17.6	4.3	e

Uric Acid




Urea

Potassium




Creatinine




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Imuchem / Simplex	7	100.0	0.0	0.0	391	5.6	e
2 Standard chemistry	11	100.0	0.0	0.0	335	4.2	e
3 Cobas	20	100.0	0.0	0.0	336	2.6	e
4 Reflotron	722	97.0	1.5	1.5	377	6.0	e
5 Fuji Dri-Chem	906	99.1	0.3	0.6	317	3.5	e
6 Spotchem/Ready	90	98.9	0.0	1.1	186	4.3	e
7 Spotchem D-Concept	336	98.8	0.3	0.9	182	4.0	e
8 Enzymatic	11	100.0	0.0	0.0	353	3.8	e
9 Piccolo	53	98.1	1.9	0.0	340	7.2	e
10 Abx Mira	9	100.0	0.0	0.0	342	4.9	e
11 Hitachi S40/M40	15	100.0	0.0	0.0	325	2.5	e
12 Autolyser/DiaSys	18	100.0	0.0	0.0	341	2.9	e
13 Other methods	4	100.0	0.0	0.0	359	4.4	e*
14 EPOC	8	100.0	0.0	0.0	332	8.2	e*

Creatinine E




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 iStat Chem8	9	100.0	0.0	0.0	332	4.9	e
2 ABL700/800	7	100.0	0.0	0.0	366	3.6	e


eGFR CKD-EPI

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Standard chemistry	68	92.6	1.5	5.9	12	10.3	e
2 Reflotron	247	95.2	2.0	2.8	11	9.2	e
3 Fuji Dri-Chem	348	94.2	0.6	5.2	13	7.1	e
4 Spotchem/Ready	162	93.9	1.2	4.9	26	6.1	e

eGFR Cockcroft-Gault




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Standard chemistry	6	83.3	0.0	16.7	14	6.7	e
2 Reflotron	19	94.7	0.0	5.3	12	14.7	e
3 Fuji Dri-Chem	49	95.9	0.0	4.1	15	10.1	e
4 Spotchem/Ready	16	93.7	0.0	6.3	27	5.3	e

eGFR MDRD


MQ tolerance : 30 %

eGFR MDRD ()


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Reflotron	6	100.0	0.0	0.0	11	6.7	e
2 Fuji Dri-Chem	6	100.0	0.0	0.0	13	11.2	e*

LDH


Magnesium




Sodium




Phosphate



Protein total




Aspartate aminotransferase




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Imuchem / Simplex	5	80.0	20.0	0.0	200	9.2	e*
2 IFCC with PP	25	100.0	0.0	0.0	175	3.3	e
3 Cobas	17	100.0	0.0	0.0	176	4.1	e
4 Reflotron	629	91.9	4.8	3.3	231	8.4	e
5 Fuji Dri-Chem	884	99.1	0.3	0.6	176	3.7	e
6 Spotchem/Ready	84	100.0	0.0	0.0	138	4.1	e
7 Spotchem D-Concept	338	99.1	0.3	0.6	135	4.6	e
8 IFCC without PP	5	100.0	0.0	0.0	171	2.5	e
9 Piccolo	54	100.0	0.0	0.0	161	3.7	e
10 Abx Mira	8	100.0	0.0	0.0	164	3.9	e
11 Hitachi S40/M40	16	100.0	0.0	0.0	179	2.2	e
12 Autolyser/DiaSys	18	100.0	0.0	0.0	172	6.3	e

Alanine aminotransferase




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Imuchem / Simplex	8	75.0	0.0	25.0	177	8.2	e*
2 IFCC with PP	23	100.0	0.0	0.0	148	6.8	e
3 Cobas	22	100.0	0.0	0.0	151	4.5	e
4 Reflotron	648	95.2	2.3	2.5	138	6.6	e
5 Fuji Dri-Chem	897	98.4	0.8	0.8	152	5.6	e
6 Spotchem/Ready	88	95.5	3.4	1.1	148	7.1	e
7 Spotchem D-Concept	340	95.6	3.8	0.6	121	8.9	e
8 Piccolo	53	98.1	1.9	0.0	140	6.2	e
9 Abx Mira	7	100.0	0.0	0.0	162	7.3	e*
10 Hitachi S40/M40	16	100.0	0.0	0.0	167	3.3	e
11 Autolyser/DiaSys	18	100.0	0.0	0.0	161	5.9	e

Triglycerides




Lithium





Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	17	100.0	0.0	0.0	1.43	3.2	e

Lactate



Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	13	100.0	0.0	0.0	3.74	3.6	e


pCO₂

pO₂


QUALAB Toleranz : 15 %

pO₂ (kPa)


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 ABL700/800	79	87.3	1.3	11.4	9.84	4.6	e
2 ABL80 FLEX	8	87.5	0.0	12.5	9.52	9.2	e*
3 ABL80 FLEX CO-OX / O	13	84.6	15.4	0.0	8.50	10.5	e*
4 ABL90 FLEX / PLUS	68	86.8	0.0	13.2	7.23	4.6	e
5 Cobas b 123	7	85.7	0.0	14.3	8.91	10.4	e*
6 Cobas b 221	6	83.3	0.0	16.7	12.76	5.9	e*
7 GEM	4	100.0	0.0	0.0	8.45	6.4	e*
8 iStat	42	69.0	16.7	14.3	11.63	10.6	e
9 EPOC	44	86.4	6.8	6.8	8.17	9.1	e

pH

Glucose BG



Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas b 123	4	100.0	0.0	0.0	14.1	1.1	e
2 iStat	11	100.0	0.0	0.0	13.0	1.1	e
3 EPOC	31	90.3	6.5	3.2	14.5	5.0	e
4 ABL700/800	69	98.6	0.0	1.4	14.3	2.0	e
5 ABL90 FLEX / PLUS	67	98.5	1.5	0.0	13.5	3.3	e


Hemoglobin BG

QUALAB Toleranz : 9 %

Hemoglobin BG (g/l)

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 ABL700/800	72	98.6	0.0	1.4	194.1	1.9	e
2 ABL90 FLEX / PLUS	67	100.0	0.0	0.0	195.0	0.5	e
3 ABL80 FLEX CO-OX / O	10	100.0	0.0	0.0	195.1	2.4	e


Potassium BG



QUALAB Toleranz : 6 %

Potassium BG (mmol/l)


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas b 123	15	100.0	0.0	0.0	5.3	2.3	e
2 iStat	21	100.0	0.0	0.0	5.4	1.5	e
3 EPOC	35	100.0	0.0	0.0	5.0	1.1	e
4 ABL700/800	72	98.6	0.0	1.4	5.5	1.1	e
5 ABL90 FLEX / PLUS	69	100.0	0.0	0.0	5.5	0.6	e
6 ABL80 FLEX CO-OX / O	6	100.0	0.0	0.0	5.1	1.1	e

Sodium BG

QUALAB Toleranz : 6 %

Sodium BG (mmol/l)

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas b 123	15	100.0	0.0	0.0	121.6	1.5	e
2 iStat	21	100.0	0.0	0.0	125.1	0.8	e
3 EPOC	33	100.0	0.0	0.0	119.5	2.7	e
4 ABL700/800	70	98.6	0.0	1.4	127.2	0.8	e
5 ABL90 FLEX / PLUS	68	100.0	0.0	0.0	126.3	0.4	e
6 ABL80 FLEX CO-OX / O	6	100.0	0.0	0.0	123.5	1.0	e


Chlorid-BG

QUALAB Toleranz : 6 %


Chlorid-BG (mmol/l)

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas b 123	4	100.0	0.0	0.0	71.8	0.9	e
2 ABL700/800	66	97.0	1.5	1.5	68.0	2.5	e
3 ABL90 FLEX / PLUS	67	100.0	0.0	0.0	64.7	1.5	e
4 ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	65.0	2.3	e*


Calcium-BG




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 GEM	4	100.0	0.0	0.0	0.27	5.4	e*
2 ABL80 FLEX	4	100.0	0.0	0.0	0.25	17.6	e*
3 Cobas b123	5	100.0	0.0	0.0	0.16	30.2	e*
4 Cobas	9	100.0	0.0	0.0	0.28	26.4	e*
5 iStat	12	100.0	0.0	0.0	0.29	2.2	e
6 EPOC	31	96.8	0.0	3.2	0.26	3.5	e
7 ABL700/800	71	100.0	0.0	0.0	0.38	8.7	e
8 ABL90 FLEX / PLUS	69	100.0	0.0	0.0	0.37	1.6	e
9 ABL80 FLEX CO-OX / O	5	100.0	0.0	0.0	0.30	11.4	e*


FHHb


Nr.	Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1	ABL80 FLEX CO-OX / O	5	100.0	0.0	0.0	21.100	0.8	e

Lactate-BG

sO2 OR


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 iStat	11	100.0	0.0	0.0	98.455	0.5	e
2 ABL700/800	52	98.1	0.0	1.9	70.090	0.1	e
3 ABL90 FLEX / PLUS	60	100.0	0.0	0.0	69.972	0.1	e
4 ABL80 FLEX CO-OX / O	9	100.0	0.0	0.0	69.900	0.1	e


FO2Hb OR

FCOHb OR

MQ tolerance : 20 %


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 ABL700/800	52	98.1	0.0	1.9	20.228	1.2	e
2 ABL90 FLEX / PLUS	60	100.0	0.0	0.0	19.948	0.8	e
3 ABL80 FLEX CO-OX / O	11	100.0	0.0	0.0	19.936	0.7	e

FMetHb OR

FHbF OR


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 ABL90 FLEX / PLUS	15	100.0	0.0	0.0	49.133	3.3	e


Bilirubin OR



Nr.	Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1	ABL90 FLEX / PLUS	25	100.0	0.0	0.0	449.8	0.5	e


Troponin I



Troponin T

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas hs STAT	9	100.0	0.0	0.0	3134.00	4.7	e


Myoglobin




QUALAB Toleranz : 30 %


Myoglobin (µg/l)

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas E / Elecsys	7	100.0	0.0	0.0	150.6	6.0	e
2 Architect	4	100.0	0.0	0.0	202.0	6.1	e

CK-MB mass

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Architect	4	100.0	0.0	0.0	35.7	6.6	e
2 Cobas E / Elecsys	4	100.0	0.0	0.0	31.3	18.9	e*


NT-proBNP

TSH

QUALAB Toleranz : 20 %

TSH (mU/l)


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas E / Elecsys	14	92.9	0.0	7.1	14.75	4.2	e
2 Architect	12	100.0	0.0	0.0	11.06	3.3	e
3 VIDAS	16	100.0	0.0	0.0	16.08	4.9	e
4 AFIAS	36	97.2	0.0	2.8	15.83	4.1	e
5 Other methods	4	75.0	0.0	25.0	13.19	8.8	e*

T3


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 AFIAS	11	90.9	9.1	0.0	2.2	8.6	e*

K06 Hormones

T4




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 AFIAS	11	100.0	0.0	0.0	268	9.8	e*

FT3

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas E / Elecsys	15	93.3	6.7	0.0	12.7	5.6	e
2 Architect	10	100.0	0.0	0.0	10.4	3.2	e
3 VIDAS	8	100.0	0.0	0.0	11.5	5.0	e

FT4




QUALAB Toleranz : 20 %


FT4 (pmol/l)

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas E / Elecsys	15	100.0	0.0	0.0	40.4	6.1	e
2 Architect	12	100.0	0.0	0.0	33.3	10.5	a
3 VIDAS	8	100.0	0.0	0.0	40.6	5.1	e
4 Other methods	4	100.0	0.0	0.0	41.1	2.7	e


Testosterone



Estradiol




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas	6	100.0	0.0	0.0	1430	3.6	e
2 Architect	4	100.0	0.0	0.0	1266	3.4	e


SHBG

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas	5	100.0	0.0	0.0	34.2	4.7	e

Cortisol




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas E / Elecsys	7	100.0	0.0	0.0	612	4.0	e
2 Architect	4	100.0	0.0	0.0	568	3.5	e

DHEAS

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas	5	100.0	0.0	0.0	9.41	3.8	e

Luteinizing hormone




QUALAB Toleranz : 24 %

Luteinizing hormone (U/I)


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Roche, Cobas	7	100.0	0.0	0.0	38.7	5.2	e
2 Architect	4	100.0	0.0	0.0	28.7	2.1	e

Follicle-stimulating hormone




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Roche, Cobas	7	100.0	0.0	0.0	23.1	3.2	e
2 Architect	4	100.0	0.0	0.0	24.2	4.9	e


Prolactine



Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas/Roche	7	100.0	0.0	0.0	34.0	6.0	e
2 Architect	4	100.0	0.0	0.0	29.3	4.2	e


HGH

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	6	100.0	0.0	0.0	15.10	5.3	e

IGF-1

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Liaison	7	100.0	0.0	0.0	104	11.3	e*


Troponin T CR




QUALAB Toleranz : 24 %


Troponin T CR (ng/l)

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas h 232	1258	96.9	2.4	0.7	255.00	10.8	e
2 Cardiac Reader	13	100.0	0.0	0.0	256.62	10.3	e


D-dimer CR

CKMB- K8


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas h 232	14	100.0	0.0	0.0	14.3	9.7	e

NT-proBNP CR


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas h 232	797	98.2	1.3	0.5	478	11.1	e
2 Cardiac Reader	5	100.0	0.0	0.0	463	9.6	e*

PCO₂ CCA

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 OPTI CCA	12	83.4	8.3	8.3	3.25	5.7	e*


PO2 CCA

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 OPTI CCA	12	91.7	0.0	8.3	18.67	3.6	e

pH CCA


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 OPTI CCA	11	72.7	18.2	9.1	7.61	0.6	e*

Potassium CCA




Nr.	Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1	OPTI CCA	5	100.0	0.0	0.0	5.9	2.3	e*

Sodium CCA




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 OPTI CCA	4	100.0	0.0	0.0	158.0	1.1	e

Ferritin




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Beckman	6	100.0	0.0	0.0	99.95	3.5	e
2 all Participants	5	80.0	0.0	20.0	104.90	6.6	e*
3 Cobas E / Elecsys	15	100.0	0.0	0.0	129.32	3.9	e
4 Architect	9	88.9	0.0	11.1	154.00	5.6	e
5 Mini Vidas	9	88.9	0.0	11.1	106.00	9.7	e*
6 AFIAS	42	97.6	2.4	0.0	93.80	6.2	e
7 Eurolyser	23	91.3	8.7	0.0	76.55	10.8	e

Vitamin B12



Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas E / Elecsys	14	92.9	0.0	7.1	383.13	9.1	e
2 Architect	11	100.0	0.0	0.0	349.88	5.1	e

Folate




QUALAB Toleranz : 24 %
(< 10.00: +/- 2.40 nmol/l)


Folate (nmol/l)

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Other methods	4	100.0	0.0	0.0	8.00	9.4	e*
2 Cobas E / Elecsys	13	76.9	15.4	7.7	10.58	16.0	e*
3 Architect	9	100.0	0.0	0.0	16.60	13.3	e*


Holotranscobalamin



Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Architect	11	100.0	0.0	0.0	120.0	7.9	e
2 all Participants	12	83.4	8.3	8.3	133.3	13.4	e*


Bilirubin total Neo

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	16	100.0	0.0	0.0	226	6.7	e

Bilirubin direct


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	15	100.0	0.0	0.0	112	6.7	e

Bilirubin neonatal



K14 Tumor Markers


PSA



Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas E / Elecsys	12	100.0	0.0	0.0	9.33	4.9	e
2 Architect	9	100.0	0.0	0.0	8.93	5.2	e
3 Qualigen	4	100.0	0.0	0.0	10.55	19.1	e*
4 AFIAS	30	96.7	0.0	3.3	9.10	4.4	e

K14 Tumor Markers


free PSA



Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas E / Elecsys	7	100.0	0.0	0.0	2.96	5.8	e
2 Architect	7	100.0	0.0	0.0	3.03	4.3	e

K14 Tumor Markers


CEA




QUALAB Toleranz : 21 %

CEA ($\mu\text{g/l}$)

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas E / Elecsys	8	100.0	0.0	0.0	24.8	4.5	e
2 Architect	6	100.0	0.0	0.0	39.2	5.7	e

CA 125


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas E / Elecsys	5	100.0	0.0	0.0	27.7	4.3	e
2 Architect	4	100.0	0.0	0.0	42.1	2.9	e

CA 15-3

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas E / Elecsys	6	100.0	0.0	0.0	52.2	8.6	e*
2 Architect	4	100.0	0.0	0.0	50.1	3.8	e

K14 Tumor Markers


AFP



Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas E / Elecsys	5	100.0	0.0	0.0	22.6	12.2	e*
2 Architect	4	100.0	0.0	0.0	22.9	3.4	e

K14 Tumor Markers


HCG qn



Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas E / Elecsys	7	100.0	0.0	0.0	27.9	2.6	e
2 VIDAS	8	100.0	0.0	0.0	10.3	9.3	e*
3 Architect	5	100.0	0.0	0.0	46.4	2.4	a
4 AFIAS	7	71.4	0.0	28.6	29.1	6.9	e

K15 Creatinkinase Activity


CK-MB




MQ tolerance : 30 %

CK-MB (U/I)


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Fuji Dri-Chem	31	100.0	0.0	0.0	78.5	4.8	e
2 Cobas/Roche	4	100.0	0.0	0.0	19.9	3.7	e

BNP

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Architect	5	100.0	0.0	0.0	675.7	6.3	e


Cholesterol PTS

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 CardioChek	11	81.8	9.1	9.1	4.23	6.2	e*


Cholesterol HDL PTS

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 CardioChek	11	72.7	0.0	27.3	1.59	12.8	e*

Triglycerides




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 CardioChek	11	100.0	0.0	0.0	1.76	6.8	e


C-Peptid

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	5	100.0	0.0	0.0	2.85	7.9	e*

Procalcitonin




Parathyroid hormone




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas PTH STAT	4	100.0	0.0	0.0	7.5	10.3	e*
2 Cobas	10	100.0	0.0	0.0	6.3	10.1	e*
3 Architect	5	100.0	0.0	0.0	12.8	10.7	e*
4 ADVIA Centaur XP/CP	4	100.0	0.0	0.0	13.9	2.7	e

Osmolality




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cryoskopy	15	100.0	0.0	0.0	640	1.8	e


Potassium-K22




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 ISE	11	100.0	0.0	0.0	3.8	1.7	e

Sodium-K22

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 ISE	11	100.0	0.0	0.0	139	0.9	e


Glucose-K22

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Standard chemistry	11	100.0	0.0	0.0	7.0	2.8	e

Urea-K22


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Standard chemistry	11	100.0	0.0	0.0	4.7	2.4	e

Osmotic Gap




Nr.	Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1	Formel 1 (2Na+K+Glu+)	11	100.0	0.0	0.0	313.7	10.1	e*

Digoxin




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Other methods	9	100.0	0.0	0.0	3.00	14.1	e*

Paracetamol




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	4	100.0	0.0	0.0	603.6	11.8	e*

Valproat


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	6	100.0	0.0	0.0	665.4	8.0	e*

Cystatin C




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	9	100.0	0.0	0.0	1.7	5.1	e

Ethanol




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Others	4	100.0	0.0	0.0	40.8	5.5	e*
2 all Participants	22	95.5	0.0	4.5	38.4	6.0	e

Calprotectin




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Bühlmann ELISA	8	87.5	12.5	0.0	446	24.0	e*
2 Bühlmann fCALturbo	6	100.0	0.0	0.0	487	6.9	e
3 Liaison	23	87.0	0.0	13.0	238	15.5	e

Cholesterol total Af/b101

QUALAB Toleranz : 10 %

Cholesterol total Af/b101 (mmol/l)

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas b101	161	99.4	0.0	0.6	4.86	2.3	e
2 Afinion	444	99.3	0.2	0.5	5.22	3.8	e


Cholesterol HDL Af/b101

QUALAB Toleranz : 21 %

Cholesterol HDL Af/b101 (mmol/l)


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas b101	160	96.9	0.6	2.5	1.01	3.8	e
2 Afinion	442	92.1	0.2	7.7	1.02	4.7	e

Tryglycerides Af/b101




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas b101	159	98.7	0.0	1.3	1.70	2.7	e
2 Afinion	444	99.3	0.0	0.7	1.66	3.8	e


Troponin I S



Nr.	Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1	Samsung LABGEO IB10	4	100.0	0.0	0.0	1257.50	5.3	e
2	AFIAS	151	85.4	7.3	7.3	3138.68	14.6	e


D-dimer qn S

Nr.	Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1	Samsung LABGEO IB10	6	66.6	16.7	16.7	0.94	10.7	e*
2	AFIAS	157	91.7	0.0	8.3	0.75	7.3	e

NT-proBNP S


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 AFIAS	117	94.8	2.6	2.6	3474.1	9.3	e

Homocystein




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	4	100.0	0.0	0.0	10.9	11.2	e*

Lipase



Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Roche	4	100.0	0.0	0.0	49.0	8.3	e*
2 Beckman	10	100.0	0.0	0.0	46.1	7.9	e*
3 Cobas	5	100.0	0.0	0.0	38.0	7.9	e*
4 Fuji Dri-Chem	139	95.7	0.7	3.6	50.7	6.6	e


Glucose CSF

QUALAB Toleranz : 9 %
(< 3.30: +/- 0.30 mmol/l)

Glucose CSF (mmol/l)


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas	4	100.0	0.0	0.0	1.74	1.7	e
2 Other methods	7	100.0	0.0	0.0	1.60	4.3	e*

Lactate CSF




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas	4	100.0	0.0	0.0	3.84	2.4	e
2 Other methods	6	100.0	0.0	0.0	3.81	4.5	e

Protein CSF




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas	4	100.0	0.0	0.0	0.87	4.1	e*
2 Other methods	6	100.0	0.0	0.0	0.92	3.4	e


CDT

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	4	100.0	0.0	0.0	0.95	9.0	e*


Tacrolimus




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	10	100.0	0.0	0.0	15.9	3.8	e

Totalprotein E


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	5	100.0	0.0	0.0	75.0	4.2	e*

Albumin E


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Electrophoresis	9	100.0	0.0	0.0	64.3	2.5	e

alpha-1-Globuline


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 capillary electropho	6	100.0	0.0	0.0	4.1	6.2	e

alpha-2-Globuline


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Electrophoresis	9	100.0	0.0	0.0	8.2	11.6	e*

beta-Globuline


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Electrophoresis	7	100.0	0.0	0.0	9.8	7.1	e

Beta-1-Globulin


Nr.	Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1	Electrophoresis	4	75.0	0.0	25.0	6.1	2.6	e

Beta-2-Globulin

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Electrophoresis	4	100.0	0.0	0.0	4.0	3.7	e


gamma-Globuline


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Electrophoresis	6	100.0	0.0	0.0	13.4	1.7	e

Immunfixation


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Interpretation	8	100.0	0.0	0.0	8	0.0	e

Folate in Erythrocytes




HbA1c sample A


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Roche, Cobas	16	100.0	0.0	0.0	7.5	2.8	e
2 HPLC	7	100.0	0.0	0.0	7.5	3.1	e*
3 Afinion	572	99.5	0.2	0.3	7.4	2.3	e
4 Cobas b101	123	99.2	0.0	0.8	7.2	2.1	e
5 DCA2000/Vantage	165	98.2	0.0	1.8	7.2	2.5	e
6 Celltac chemi	19	100.0	0.0	0.0	7.2	3.7	e
7 NycoCard	37	86.5	2.7	10.8	7.3	4.8	e
8 Eurolyser	10	90.0	0.0	10.0	7.3	4.9	e*
9 Hemocue HbA1c 501	6	83.3	16.7	0.0	7.4	5.5	e*
10 A1c Now	219	81.3	14.6	4.1	6.9	6.0	e
11 AFIAS	59	93.2	5.1	1.7	7.1	4.2	e
12 Others	12	91.7	8.3	0.0	7.3	5.6	e*
13 Spinit	12	75.0	8.3	16.7	7.4	3.4	a

HbA1c sample B

Gallensäure



Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	9	100.0	0.0	0.0	62.1	9.5	e


BNP

QUALAB Toleranz : 27 %
(< 75.0: +/- 20.0 ng/l)


BNP (ng/l)

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Triage	16	87.4	6.3	6.3	5.0	81.5	a


Troponin Triage




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Triage high sensitiv	4	75.0	0.0	25.0	38.60	9.9	a
2 Triage SOB/Cardiac	5	40.0	20.0	40.0	280.00	14.2	e*
3 Triage Next Gen	18	88.9	0.0	11.1	10.00	0.0	e

NT-pro BNP

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Triage	10	100.0	0.0	0.0	433	8.9	e


D-dimer Triage

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Triage	31	100.0	0.0	0.0	553.48	9.6	e

CK-MB Triage


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Triage	7	100.0	0.0	0.0	9.5	18.3	e*


Myoglobin Triage



Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Triage	7	85.7	14.3	0.0	167.0	16.3	e*


Vitamin D 25 (OH)




AMH

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	10	100.0	0.0	0.0	4.4	2.1	e

Calcitonin




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	4	100.0	0.0	0.0	12.9	5.8	e


IGF-BP3

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	4	100.0	0.0	0.0	3.71	14.0	e*


Anti Thyreoglobulin




Nr.	Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1	Cobas	8	100.0	0.0	0.0	218	5.4	e

Anti TPO

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas	7	100.0	0.0	0.0	267	6.9	e*


TRAK

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Kryptor	4	100.0	0.0	0.0	2.48	12.1	e*

Creatinine WB

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Statsensor i / Nova	43	79.1	11.6	9.3	129	11.3	e

Calcium-Urine




MQ tolerance : 9 %

Calcium-Urine (mmol/l)


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Standard chemistry	16	100.0	0.0	0.0	2.14	4.1	e

Chloride-Urine




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Standard chemistry	5	100.0	0.0	0.0	160	0.5	e
2 Cobas	7	100.0	0.0	0.0	154	2.7	e

Glucose-Urine




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Standard chemistry	16	100.0	0.0	0.0	9.5	3.0	e

Magnesium-Urine




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Standard chemistry	7	100.0	0.0	0.0	2.81	3.1	e

Osmolality-Urine




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cryoskopy	13	100.0	0.0	0.0	653	1.1	e

Phosphate-Urine




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Standard chemistry	16	100.0	0.0	0.0	12.9	2.8	e

Potassium-Urine



Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	22	100.0	0.0	0.0	52	3.3	e

Protein-Urine




QUALAB Toleranz : 20 %

Protein-Urine (mg/l)


Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Cobas/Roche	14	100.0	0.0	0.0	342.5	3.0	e
2 Standard chemistry	9	100.0	0.0	0.0	426.5	1.3	e

Sodium-Urine




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 all Participants	23	100.0	0.0	0.0	132	1.4	e

Urea-Urine




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Standard chemistry	19	100.0	0.0	0.0	204	3.7	e

Uric Acid-Urine




Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Standard chemistry	15	100.0	0.0	0.0	0.91	5.8	e


Specific Gravity-Urine



Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 Refractometer	6	100.0	0.0	0.0	1.018	0.1	e

Creatinine U

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 AFIAS	8	100.0	0.0	0.0	36.6	10.8	e*
2 Afinion	437	95.4	0.9	3.7	36.6	8.8	e
3 Sysmex U	19	63.2	0.0	36.8	30.0	0.0	e
4 Other methods	4	75.0	0.0	25.0	35.0	1.6	a
5 NycoCard	4	100.0	0.0	0.0	30.5	12.3	e*
6 Turbidimetry	24	95.8	0.0	4.2	34.6	8.4	e
7 DCA2000/Vantage	143	96.5	1.4	2.1	33.9	7.4	e
8 Siemens Clinitek	12	66.7	0.0	33.3	30.1	0.9	e

Creatinin Urin

QUALAB Toleranz : 21 %

Creatinin Urin (mmol/l)

Nr. Methode	Total	% Erfüllt	% ungen.	% Ausr	Zielwert	VK%	Typ
1 DCA2000/Vantage	145	95.2	0.0	4.8	4.7	4.6	e
2 Afinion	436	97.5	0.0	2.5	4.1	4.2	e
3 Standard chemistry	34	97.1	2.9	0.0	4.4	6.6	e
4 Sysmex U	18	77.8	0.0	22.2	4.4	0.0	e
5 Aution Eleven	4	100.0	0.0	0.0	4.4	7.3	e*
6 Siemens Clinitek	12	58.3	0.0	41.7	4.4	0.2	e